EDITORIAL A Role for Pharmacogenetics? See Article by Parish, Hopewell, and Hill et al Michael B. Boffa, PhD Marlys L. Koschinsky, PhD e are on the cusp of having elevated plasma concentrations of lipoprotein(a) as a therapeutic target for cardiovascular disease (CVD). WRecent large population studies and meta-analyses, genome-wide asso- ciation studies, and Mendelian randomization studies have identified elevated lipoprotein(a) as an independent, causal risk factor for coronary heart disease and other atherothrombotic disorders. Elevated lipoprotein(a) is also emerging as a key risk factor for calcific aortic valve disease. Several therapeutic modalities capable of lowering lipoprotein(a) are in the marketplace or are in clinical trials. Yet, sev- eral obstacles remain. Most importantly, it has not been directly demonstrated that lowering lipoprotein(a) produces a clinical benefit, and to what extent lipoprotein(a) must be lowered to derive such a benefit. Beyond this, there remain fundamental unanswered questions on how lipoprotein(a) concentrations are established and the mechanisms underlying the lipoprotein(a)-lowering effects of current therapies. The article by Parish et al in this issue, describing a substudy of the Heart Protec- tion Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2- THRIVE) randomized controlled trial of niacin/laropiprant, sheds interesting new
Circulation: Cardiovascular Genetics – Wolters Kluwer Health
Published: Feb 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud